Gender-different effect of Src family kinases antagonism on photophobia and trigeminal ganglion activity.

Autor: Huang Z; Department of Biological Sciences, School of Science, Centre for Neuroscience, Xi'an Jiaotong-Liverpool University, Suzhou, China.; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Yao J; Department of Biological Sciences, School of Science, Centre for Neuroscience, Xi'an Jiaotong-Liverpool University, Suzhou, China.; Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, China., Nie L; Department of Biological Sciences, School of Science, Centre for Neuroscience, Xi'an Jiaotong-Liverpool University, Suzhou, China.; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Nie X; Department of Biological Sciences, School of Science, Centre for Neuroscience, Xi'an Jiaotong-Liverpool University, Suzhou, China., Xiong X; Department of Biological Sciences, School of Science, Centre for Neuroscience, Xi'an Jiaotong-Liverpool University, Suzhou, China., Kõks S; Centre for Molecular Medicine and Innovative Therapeutics, Perron Institute for Neurological and Translational Science, Murdoch University, Perth, WA, Australia., Quinn JP; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Kanhere A; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Wang M; Department of Biological Sciences, School of Science, Centre for Neuroscience, Xi'an Jiaotong-Liverpool University, Suzhou, China. minyan.wang@xjtlu.edu.cn.; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK. minyan.wang@xjtlu.edu.cn.

Publikováno v: The journal of headache and pain [J Headache Pain] 2024 Oct 11; Vol. 25 (1), pp. 175. Date of Electronic Publication: 2024 Oct 11.

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition.

Autor: Song X; Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA., Zhou Z; Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA., Elmezayen A; Departments of Biochemistry and Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA., Wu R; Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA., Yu C; Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA., Gao B; Hamon Center for Therapeutic Oncology Research, Department of Pharmacology, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA., Minna JD; Hamon Center for Therapeutic Oncology Research, Department of Pharmacology, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA., Westover KD; Departments of Biochemistry and Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA., Zeh HJ; Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA., Kroemer G; Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France., Heasley LE; Department of Craniofacial Biology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.; Eastern Colorado VA Healthcare System, Rocky Mountain Regional VA Medical Center, Aurora, CO 80045, USA., Kang R; Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA., Tang D; Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Publikováno v: Science advances [Sci Adv] 2024 Dec 13; Vol. 10 (50), pp. eadq4274. Date of Electronic Publication: 2024 Dec 11.

Adaptor protein CEMIP reduces the chemosensitivity of small cell lung cancer via activation of an SRC-YAP oncogenic module.

Autor: Shen XJ; Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China.; Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China., Wei HL; Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China., Mo XC; Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China.; Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China., Mo XX; Department of Pharmacology, Maternity and Child Health Care of Guangxi Zhuang Autonomous Region, Nanning, 530021, China., Li L; Department of Pharmacology, Guangxi Institute of Chinese Medicine & Pharmaceutical Science, Nanning, 530001, China., He JC; Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China., Wei XY; Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China., Qin XJ; Department of Pharmaceutical Analysis, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China., Xing SP; Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China., Luo Z; Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China. luozhuo@gxmu.edu.cn., Chen ZQ; Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China. chenzhiquan@stu.gxmu.edu.cn., Yang J; Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China. jieyang2016@gxmu.edu.cn.; Guangxi Key Laboratory of Drug Basic Research for Prevention and Treatment of Geriatric Diseases, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China. jieyang2016@gxmu.edu.cn.; The Laboratory of Toxicology of Traditional Chinese Medicine, Leve III Laboratory of National Administration of Traditional Chinese Medicine, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China. jieyang2016@gxmu.edu.cn.

Publikováno v: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2024 Dec; Vol. 45 (12), pp. 2657-2671. Date of Electronic Publication: 2024 Jul 23.

The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.

Autor: Egeland EV; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. e.v.egeland@ous-research.no., Seip K; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Skourti E; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Insitute for Clinical Medicine, University of Oslo, Oslo, Norway., Øy GF; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Pettersen SJ; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Pandya AD; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Dahle MA; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Insitute for Clinical Medicine, University of Oslo, Oslo, Norway., Haugen MH; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway., Kristian A; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Nakken S; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway., Engebraaten O; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Insitute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway., Mælandsmo GM; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Medical Biology, Faculty of Health Sciences, The Arctic University of Norway-University of Tromsø, Tromsø, Norway., Prasmickaite L; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Publikováno v: British journal of cancer [Br J Cancer] 2024 Nov; Vol. 131 (10), pp. 1656-1667. Date of Electronic Publication: 2024 Oct 10.

Src inhibition modulates AMBRA1-mediated mitophagy to counteract endothelial-to-mesenchymal transition in renal allograft fibrosis.

Autor: Gui Z; Department of Urology, The Second Affiliated Hospital with Nanjing Medical University, Nanjing, China.; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Liu X; Department of Urology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, China.; Department of Urology, Affiliated Clinical College of Xuzhou Medical University, Huai'an, China., Xu Z; Department of Urology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China., Feng D; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Hang Z; Department of Urology, The Second Affiliated Hospital with Nanjing Medical University, Nanjing, China., Zheng M; Department of Urology, The Second Affiliated Hospital with Nanjing Medical University, Nanjing, China., Chen H; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Fei S; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Sun L; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Tao J; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Han Z; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Ju X; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Gu M; Department of Urology, The Second Affiliated Hospital with Nanjing Medical University, Nanjing, China.; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Tan R; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China., Wang Z; Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.

Publikováno v: Cell proliferation [Cell Prolif] 2024 Nov; Vol. 57 (11), pp. e13699. Date of Electronic Publication: 2024 Jun 29.